Next Article in Journal
Application of the Antibody-Inducing Activity of Glycosphingolipids to Human Diseases
Previous Article in Journal
Cancer-Associated Adipocytes in Breast Cancer: Causes and Consequences
Article

Reduced Claudin-12 Expression Predicts Poor Prognosis in Cervical Cancer

1
Department of Basic Pathology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan
2
Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan
3
Department of Diagnostic Pathology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editors: Massimiliano Fambrini, Flavia Sorbi and Felice Petraglia
Int. J. Mol. Sci. 2021, 22(7), 3774; https://doi.org/10.3390/ijms22073774
Received: 6 March 2021 / Revised: 1 April 2021 / Accepted: 3 April 2021 / Published: 6 April 2021
(This article belongs to the Section Biochemistry)
Background: Within the claudin (CLDN) family, CLDN12 mRNA expression is altered in various types of cancer, but its clinicopathological relevance has yet to be established due to the absence of specific antibodies (Abs) with broad applications. Methods: We generated a monoclonal Ab (mAb) against human/mouse CLDN12 and verified its specificity. By performing immunohistochemical staining and semiquantification, we evaluated the relationship between CLDN12 expression and clinicopathological parameters in tissues from 138 cases of cervical cancer. Results: Western blot and immunohistochemical analyses revealed that the established mAb selectively recognized the CLDN12 protein. Twenty six of the 138 cases (18.8%) showed low CLDN12 expression, and the disease-specific survival (DSS) and recurrence-free survival rates were significantly decreased compared with those in the high CLDN12 expression group. We also demonstrated, via univariable and multivariable analyses, that the low CLDN12 expression represents a significant prognostic factor for the DSS of cervical cancer patients (HR 3.412, p = 0.002 and HR 2.615, p = 0.029, respectively). Conclusions: It can be concluded that a reduced CLDN12 expression predicts a poor outcome for cervical cancer. The novel anti-CLDN12 mAb could be a valuable tool to evaluate the biological relevance of the CLDN12 expression in diverse cancer types and other diseases. View Full-Text
Keywords: claudin; CLDN12; gynecological cancer; tight junction; biomarker; squamous cell carcinoma; adenocarcinoma claudin; CLDN12; gynecological cancer; tight junction; biomarker; squamous cell carcinoma; adenocarcinoma
Show Figures

Figure 1

MDPI and ACS Style

Rahman, A.; Kobayashi, M.; Sugimoto, K.; Endo, Y.; Kojima, M.; Furukawa, S.; Watanabe, T.; Soeda, S.; Hashimoto, Y.; Fujimori, K.; Chiba, H. Reduced Claudin-12 Expression Predicts Poor Prognosis in Cervical Cancer. Int. J. Mol. Sci. 2021, 22, 3774. https://doi.org/10.3390/ijms22073774

AMA Style

Rahman A, Kobayashi M, Sugimoto K, Endo Y, Kojima M, Furukawa S, Watanabe T, Soeda S, Hashimoto Y, Fujimori K, Chiba H. Reduced Claudin-12 Expression Predicts Poor Prognosis in Cervical Cancer. International Journal of Molecular Sciences. 2021; 22(7):3774. https://doi.org/10.3390/ijms22073774

Chicago/Turabian Style

Rahman, Abidur, Makoto Kobayashi, Kotaro Sugimoto, Yuta Endo, Manabu Kojima, Shigenori Furukawa, Takafumi Watanabe, Shu Soeda, Yuko Hashimoto, Keiya Fujimori, and Hideki Chiba. 2021. "Reduced Claudin-12 Expression Predicts Poor Prognosis in Cervical Cancer" International Journal of Molecular Sciences 22, no. 7: 3774. https://doi.org/10.3390/ijms22073774

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop